Android app Apple app link

Fulcrum Therapeutics, Inc. (FULC) Analyst Forecast

NASDAQ Currency in USD Disclaimer
Add to Alerts ADD TO LIST

$12.90

$0.02 (-0.16%)
Last update: 01:26 PM EST
Day's range
$12.73
Day's range
$13

Recent Analyst Forecasts and Stock Ratings

Date Brokerage Firm Analyst Name Price Target Price when Posted Upside/Downside
on Report Date		 Details
12/08/2025 Cantor Fitzgerald Kristen Kluska $24.00 $13.74   74.67%
11/24/2025 H.C. Wainwright Andrew Fein $18.00 $11.29   59.43%
05/29/2025 Piper Sandler Edward Tenthoff $9.00 $7.09   27.03%
05/23/2025 Leerink Partners Joseph Schwartz $12.00 $6.44   86.34%
09/13/2024 H.C. Wainwright Andrew Fein $4.00 $3.44   16.28%
09/12/2024 RBC Capital Gregory Renza $4.00 $3.44   16.28%
09/12/2024 Stifel Nicolaus Dae Gon Ha downgraded Fulcrum Therapeutics $3.00 $3.55   -15.59%
09/12/2024 Bank of America Securities Tazeen Ahmad $2.00 $3.44   -41.86%
09/09/2024 Bank of America Securities Tazeen Ahmad $10.00 $8.61   16.21%
09/03/2024 RBC Capital Gregory Renza $15.00 $8.37   79.15%
05/20/2024 Cantor Fitzgerald Kristen Kluska $23.00 $7.55   204.64%
05/13/2024 Goldman Sachs Corinne Jenkins $15.00 $7.35   104.08%
05/13/2024 Stifel Nicolaus Dae Gon Ha $22.00 $7.48   194.12%
03/13/2024 RBC Capital Gregory Renza $14.00 $11.36   23.24%
11/08/2022 Piper Sandler Edward Tenthoff $18.00 $6.37   182.8%

Fulcrum Therapeutics, Inc. FAQ's

Fulcrum Therapeutics, Inc. has been rated by research analysts at Truist Financial, Stifel Nicolaus, Cantor Fitzgerald, RBC Capital, Piper Sandler, H.C. Wainwright in the past 90 days.

Exclusive Content

Access to this content is reserved for premium members. Unlock all features by upgrading to a premium membership.

Get the App

To join as a premium member, please download our app and complete your membership purchase there.